Antares Pharma to Present at the Jefferies 2015 Global Healthcare Conference

EWING, N.J.--(BUSINESS WIRE)-- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that James E. Fickenscher, Senior Vice President and Chief Financial Officer, will present at the Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015 at 12:30 p.m. Eastern Time.

A live webcast of the presentation will be available via the webcast tab under the Investor Information page of the Antares website, www.antarespharma.com. A replay of the webcast will also be archived on Antares’ website for 90 days following the presentation.

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company’s product, OTREXUP™ (methotrexate) injection for subcutaneous use, is approved in the U.S. for the treatment of adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. Antares Pharma is also developing QuickShot® Testosterone for testosterone replacement therapy, and VIBEX® Sumatriptan for the acute treatment of migraines. The Company's technology platforms include VIBEX® disposable auto injectors, disposable multi-use pen injectors and reusable needle-free injectors. Antares Pharma has a multi-product deal with Teva Pharmaceutical Industries, Ltd. that includes VIBEX® epinephrine, exenatide multi-dose pen, and another undisclosed multi-dose pen. Our reusable needle-free injector for use with human growth hormone (hGH) is sold worldwide by Ferring B.V.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150528005030/en/

Antares Pharma, Inc.
Jack Howarth
Vice President, Corporate Affairs
609-359-3016
[email protected]

Source: Antares Pharma, Inc.

You May Also Be Interested In

• Amid a Changing Global Landscape, Countries Seek Investment Opportunities at CIFIT
• CereBree Launches AI Cognitive Layer for Enterprise and Human Intelligence, Backed by $CRX Utility Token
• Como elegir una firma de fondeo en 2026: lo que el trader deberia exigir antes de pagar una evaluacion